1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Synmosa Biopharma Corp

Synmosa Biopharma Corp

TTPEX:4114
29.20
TWD
-0.20
(-0.68%)
1.10EPS
18.56P/E
14.87BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.48
4.76
6.23
5.56
5.19
6.48
7.41
7.69
7.25
9.99
11.27
11.83
12.34
12.63
Basic EPS, GAAP
0.23
0.36
0.11
0.49
0.01
1.18
0.13
1.61
0.68
1.82
1.3
1.46
1.64
1.56
Free Cash Flow per Basic Share
-1.1
-3.67
-1.35
-0.56
-1.34
-0.96
-0.68
0.2
0.7
1.02
0.53
1.09
0.26
0.11
Dividend per Share
0.07
0.07
0.08
0.08
0.09
0.1
0.11
0.12
0.18
0.34
0.43
0.49
0.54
- -
Book Value per Share
5.32
6.63
6.57
7.41
7.3
8.39
8.37
10.02
10.56
11.93
14.12
15.17
17.06
16.89
Tangible Book Value per Share
4.97
5.93
5.83
6.95
6.48
7.54
6.97
8.8
9.43
10.65
12.94
14.1
16.21
15.67
Basic Weighted Avg Shares
279
310
285
335
358
365
362
395
446
439
456
469
502
529
Sales/Revenue/Turnover
1,249
1,476
1,776
1,865
1,861
2,363
2,680
3,038
3,235
4,386
5,140
5,550
6,189
6,679
Operating Margin (%)
3.26
-3.49
0.94
-2.7
-6.23
-2.62
-4.34
3.93
5.73
10.37
12.07
13.32
12.57
10.7
Depreciation Expense
46
68
88
105
119
148
262
302
302
320
340
342
343
356
Net Income, GAAP
63
110
32
165
5
431
47
638
304
799
595
685
822
827
Effective Tax Rate (%)
10.57
25.02
- -
20.3
- -
9.5
- -
4.63
24.57
14.64
32.65
28.86
22.66
25.37
Profit Margin (%)
5.04
7.47
1.78
8.86
0.25
18.23
1.76
21
9.39
18.22
11.57
12.34
13.28
12.38
Working Capital
1,148
802
505
713
-172
-134
113
1,423
1,210
1,686
2,421
2,945
4,406
3,581
LT Debt
543
675
864
1,343
1,537
1,043
1,665
2,807
2,278
2,170
1,459
1,779
1,571
1,810
Total Equity
2,194
3,160
3,014
4,353
3,965
4,485
4,813
5,955
6,095
6,649
8,101
8,399
10,099
9,867
Return on Invested Capital (%)
1.5
-1.1
- -
1.73
- -
-0.85
- -
3.22
1.43
3.91
3.98
4.84
5.05
4.12
Return on Capital (%)
3.44
4.83
- -
4.95
- -
8.89
- -
9.83
5.53
10.52
8.07
8.76
9.11
8.74
Return on Common Equity (%)
4.22
5.25
1.36
6.21
0.16
14.19
1.41
15.99
6.6
15.95
9.9
9.84
10.29
9.7

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
945
1,121
1,548
LT Borrowings
1,537
1,401
1,780
LT Finance Leases
34
28
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
514
511
512
Market Capitalization
15,415
14,614
14,866

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,669
6,462
7,053
Cash, Cash Equivalents & STI
2,931
2,706
2,780
Accounts Receivable, Net
1,293
1,254
1,588
Inventories
2,192
2,200
2,425
Total Current Liabilities
2,262
2,485
3,471
Payables & Accruals
- -
- -
- -
ST Debt
945
1,121
1,548
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.69%
11.44%
20.25%
Free Cash Flow
25.61%
67.71%
-74.47%
Net Income, GAAP
1,070.47%
24.04%
20.03%
Sales/Revenue/Turnover
13.73%
15.75%
11.53%
Total Cash Common Dividend
29.82%
45.7%
19.18%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,281
1,333
1,424
1,512
5,550
2025
1,448
1,613
1,537
1,592
6,189
2026
1,628
1,922
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.39
0.39
0.34
0.27
1.46
2025
0.43
0.39
0.4
0.35
1.64
2026
0.38
0.43
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.49
2025
- -
- -
- -
- -
0.54
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chih Hui Lin
Full Time Employees
586
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 396, Neihu Road Taipei TPE Taiwan 114
IPO Date
Sep 9, 2002
Website
synmosa.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Synmosa Biopharma Corporation (4114.TWO) researches, develops, manufactures, markets and distributes specialty pharmaceutical and healthcare products under the Synmosa brand primarily in Taiwan. The company offers a comprehensive portfolio spanning cardiovascular treatments for high blood pressure, high blood sugar, high cholesterol and heart failure; respiratory products including metered dose inhalers, nasal sprays and granules with leading domestic market share; urology and women's healthcare solutions encompassing sex hormones produced in a dedicated international-standard facility; oncology therapies; gastrointestinal drugs; antibiotics; and additional offerings such as effervescent tablets, contract manufacturing services, cosmetics, animal medicines, chemical food additives and beverages. Founded in 1980 and headquartered in Taipei's Neihu District, Taiwan, Synmosa operates manufacturing facilities in Hsinchu Hukou, Taichung and New Taipei City, with geographic reach extending to Hong Kong, China, Vietnam, South Africa, Thailand, Singapore, Malaysia and partners in Finland, France, Japan and Australia. In recent developments, Synmosa announced in September 2025 a public tender offer to acquire 15-30% of Genovate Biotechnology Co. at a 30% premium to enhance drug supply resilience, production efficiency and Asian market expansion through Genovate's PIC/S GMP-certified plants focused on new chemical entities and generics. The company maintains strategic alliances, including introductions of patented drugs like Japan partner Kissei's oral GnRH antagonist Yselty for uterine fibroids in Taiwan, and continues vertical integration via prior majority stakes in subsidiaries such as Seven Star Pharmaceutical for active pharmaceutical ingredient production.